- By FYH News Team
[ad_1]
doi: 10.1097/GME.0000000000002267.
Online ahead of print.
Affiliations
Item in Clipboard
Menopause.
.
Abstract
Use of menopausal hormone therapy (HT) fell precipitously after 2002, largely as a result of the Women’s Health Initiative’s report claiming that the combination of conjugated equine estrogen (CEE) and medroxyprogesterone acetate increased breast cancer risk and did not improve quality of life. More recently, Women’s Health Initiative (WHI) publications acknowledge HT as the most effective treatment for managing menopausal vasomotor symptoms and report that CEE alone reduces the risk of breast cancer by 23% while reducing breast cancer death by 40%. Their sole remaining concern is a small increase in breast cancer incidence with CEE and medroxyprogesterone acetate (1 per 1,000 women per year) but with no increased risk of breast cancer mortality. This article closely examines evidence that calls even this claim of breast cancer risk into serious question, including the WHI’s reporting of nonsignificant results as if they were meaningful, a misinterpretation of its own data, and the misleading assertion that the WHI’s findings have reduced the incidence of breast cancer in the United States. A generation of women has been deprived of HT largely as a result of this widely publicized misinterpretation of the data. This article attempts to rectify this misunderstanding, with the goal of helping patients and physicians make informed joint decisions about the use of HT.
Copyright © 2023 by The Menopause Society.
Conflict of interest statement
Financial disclosure/conflicts of interest: R.D.L. was funded by the National Heart, Lung, and Blood Institute as a principal investigator in the Women’s Health Initiative 1993 to 2005 but has not received funding related to this article from any source for more than 5 years. The other authors have nothing to disclose.
References
-
-
Brown S. Shock, terror and controversy: how the media reacted to the Women’s Health Initiative. Climacteric 2012;15:275–280. doi: 10.3109/13697137.2012.660048
–
DOI
-
-
-
Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333. doi: 10.1001/jama.288.3.321
–
DOI
-
-
-
Chlebowski RT, Aragaki AK. The Women’s Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context. Menopause 2023;30:454–461. doi: 10.1097/GME.0000000000002154
–
DOI
-
-
-
Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103–115. doi: 10.1016/j.maturitas.2006.05.004
–
DOI
-
-
-
Langer RD, Manson JE, Allison MA. Have we come full circle — or moved forward? The Women’s Health Initiative 10 years on. Climacteric 2012;15:206–212. doi: 10.1016/j.maturitas.2006.05.004
–
DOI
-
[ad_2]
Source link
Trending Topics
Features
- Drive Toolkit
Download and distribute powerful vaccination QI resources for your community.
- Health Champions
Sign up now to support health equity and sustainable health outcomes in your community.
- Cancer Early Detection
MCED tests use a simple blood draw to screen for many kinds of cancer at once.
- PR
FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.
- Medicare
Discover an honest look at our Medicare system.
- Alliance for Representative Clinical Trials
ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.
- Reducing Patient Risk
The single most important purpose of our healthcare system is to reduce patient risk for an acute event.
- Jessica Wilson
- Subash Kafle
